Melanoma brain metastases (MBMs) represent one of the most formidable challenges in modern oncology, affecting up to 60% of patients with advanced melanoma and serving as a leading cause of morbidity and mortality.¹ Melanoma has a propensity for spreading to the central nervous system (CNS), leading to high morbidity, mortality as well as resistance to therapy due to the blood-brain barrier.² Despite significant advances in systemic therapies for melanoma, the treatment of brain metastases remains complex due to the unique anatomical and physiological barriers that limit drug penetration and the aggressive nature of intracranial disease.

The blood-brain barrier challenge

Traditional systemic therapy with such chemotherapy agents such as dacarbazine, paclitaxel, or carboplatin has limited activity in melanoma brain metastases because of complicated drug delivery to the brain due to the blood-brain barrier (BBB).³ The blood-brain barrier presents a formidable obstacle to therapeutic intervention, selectively preventing many systemic agents from reaching therapeutic concentrations within the CNS. For a drug administered via blood to successfully treat brain metastases, it must first pass the BBB, and then the barrier formed by the microenvironment around the tumor, and reach the tumor in sufficient quantity. While tumors can cause damage to the BBB, this does not always occur.⁴

Historically, the prognosis for patients with melanoma brain metastases has been poor. The median overall survival (OS) from the onset of brain metastases was 11 months, with patient survival durations of 4-6 months reported in pre-immune checkpoint blockade studies.^3,5 However, the therapeutic landscape has evolved dramatically with the introduction of immune checkpoint inhibitors (ICIs) and targeted therapies that demonstrate meaningful intracranial efficacy.

Current treatment paradigms

Immune checkpoint inhibitors: the CheckMate 204 breakthrough

The CheckMate 204 trial (NCT02320058) has fundamentally transformed the treatment approach for asymptomatic melanoma brain metastases.⁶ This landmark Phase II study demonstrated the remarkable efficacy of combination nivolumab plus ipilimumab in patients with untreated brain metastases. The study enrolled patients into two distinct cohorts: asymptomatic patients without neurological symptoms or baseline corticosteroid use, and symptomatic patients with stable neurological symptoms who could receive low-dose dexamethasone.

The results for asymptomatic patients were particularly impressive. Among 94 patients with a median follow-up of 14.0 months, the rate of intracranial clinical benefit was 57% (95% confidence interval [CI], 47 to 68); the rate of complete response (CR) was 26%, the rate of partial response (PR) was 30%, and the rate of stable disease for at least 6 months was 2%.⁶ Perhaps most remarkably, the durable 3-year response, OS, and progression-free survival (PFS) rates for asymptomatic patients support first-line use of nivolumab plus ipilimumab. Long-term follow-up data revealed exceptional durability of responses. Intracranial objective response rate (ORR) of 53.5% and a 3-year OS rate of 71.9% in asymptomatic patients established this combination as a new standard of care for this patient population.⁷

The ABC study: confirmatory evidence

The Anti-PD1 Brain Collaboration (ABC) study (NCT02374242) provided confirmatory evidence for the efficacy of ICIs in melanoma brain metastases.⁸ Preliminary data from the ABC (76 pts) and CheckMate 204 (94 pts) trials showed that nivolumab and nivolumab plus ipilimumab have activity in active melanoma brain metastases, with durable responses in a subset of patients.^7,8 The 5-year follow-up from the ABC study demonstrated durable responses in the majority of patients who received ipilimumab plus nivolumab upfront, reinforcing the long-term benefits observed in CheckMate 204.⁸

Limitations in symptomatic disease

While the results in asymptomatic patients are encouraging, the treatment of symptomatic brain metastases remains challenging. Nivolumab plus ipilimumab provides durable clinical benefit for asymptomatic patients with MBM and should be considered for first-line therapy. This regimen has limited activity in MBM patients with neurologic symptoms and/or requiring corticosteroids, supporting the need for alternative approaches.⁹

Sunandana Chandra, MD, MS, Northwestern University, Chicago, IL, discusses challenges in the management of symptomatic brain metastases.

Targeted therapy for BRAF-mutated melanoma brain metastases

For patients harboring BRAF V600 mutations, which occur in approximately 40-50% of melanomas, targeted therapy represents a crucial treatment option.¹⁰ The combination of BRAF and MEK inhibitors has demonstrated significant intracranial activity in multiple clinical trials.

The COMBI-MB experience

The COMBI-MB trial specifically evaluated dabrafenib plus trametinib in patients with BRAF V600-mutant melanoma brain metastases.¹¹ This open-label, Phase II study (NCT02039947) evaluated dabrafenib 150 mg twice daily plus trametinib 2 mg once daily in four melanoma patient cohorts, including both asymptomatic and symptomatic patients with varying mutation subtypes.

The results demonstrated substantial intracranial activity. For patients with BRAF V600-mutant melanoma and brain metastases, the combination of dabrafenib and trametinib in the COMBI-MB trial showed a high intracranial response rate (up to 59%), regardless of the presence of symptoms.¹¹ However, the durability of responses in patients with brain metastases was shorter compared to those without CNS involvement.

Alternative BRAF/MEK combinations

The combination of encorafenib plus binimetinib has demonstrated clinical activity and tolerability in the Phase III COLUMBUS study (NCT01909453) in patients with BRAF V600–mutated melanoma. Although brain metastases patients were excluded from the pivotal COLUMBUS trial, real-world evidence and case series have suggested intracranial activity.¹²

The E-BRAIN/GEM1802 study provided prospective evidence for encorafenib plus binimetinib activity in brain metastases.¹³ The primary endpoint of intracranial response rate was achieved, with 70.8% of both asymptomatic and symptomatic patients exhibiting a response to treatment and surpassing the expected futility threshold. The study also demonstrated the feasibility of combining targeted therapy with radiotherapy.

Emerging therapeutic approaches

Tumor-infiltrating lymphocyte therapy

Lifileucel represents a groundbreaking advancement in melanoma treatment as the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy.¹⁴ This autologous cellular therapy has demonstrated remarkable efficacy in heavily pretreated patients with advanced melanoma.¹⁵

In the pivotal C-144-01 study, lifileucel demonstrated durable responses and addresses a major unmet need in patients with metastatic melanoma with limited treatment options after approved therapy, including the primary refractory to anti-PD-1 or PD-L1 therapy subset. At 5-year follow-up, the objective response rate was 31.4%, and overall, 79.3% of patients had tumor burden reduction.¹⁶

Lifileucel in brain metastases

While patients with active brain metastases were excluded from the initial lifileucel trials, emerging evidence suggests potential benefit in this challenging population. A single-center pilot trial (NCT05640193) is enrolling up to 10 patients with asymptomatic melanoma brain metastases from non-uveal melanoma to receive lifileucel.¹⁷ This represents the first prospective evaluation of TIL therapy specifically in patients with melanoma brain metastases.

Allison Betof Warner, MD, Stanford Cancer Center, Stanford, CA, provides a brief overview on lifileucel, for melanoma brain metastases (MBM).

Novel mechanisms and therapeutic targets

Recent advances in understanding the unique molecular landscape of brain metastatic melanoma have unveiled several promising therapeutic targets currently under investigation. The PI3K/AKT/mTOR pathway shows frequent activation in brain metastases compared to extracranial metastases and primary tumors, and is particularly critical during early steps of brain colonization including intravascular arrest and extravasation.¹⁸ Low-dose dual PI3K/mTOR inhibition in preventive schedules has demonstrated efficacy in reducing brain metastasis formation in preclinical models, while the brain-penetrant pan-AKT inhibitor GDC-0068 has shown promising antitumor activity in PIK3CA-mutant breast cancer brain metastases, providing rationale for similar approaches in melanoma.¹⁹

Emerging immunotherapeutic and targeted approaches

Novel immunotherapeutic approaches are exploring combination strategies to overcome the immunosuppressive brain metastatic niche. Combined nivolumab and ipilimumab has demonstrated intracranial clinical benefit in patients with untreated melanoma brain metastases,²⁰ while immunotherapy combined with stereotactic radiosurgery has shown promise for improving disease control.²¹

Antibody-drug conjugates and bispecific antibodies designed with enhanced CNS penetration represent an emerging frontier, with strategies including conjugation to blood-brain barrier-penetrating peptide shuttles such as angiopep-2 and melanotransferrin showing up to 68% reduction in brain metastases in preclinical models.^22,23

Future perspectives

The treatment landscape for melanoma brain metastases has been revolutionized by the introduction of immune checkpoint inhibitors and targeted therapies that demonstrate meaningful CNS activity. The emergence of lifileucel as the first approved TIL therapy represents a new paradigm in cellular immunotherapy, with early investigations suggesting potential benefit even in the challenging brain metastases population. Despite remarkable progress, significant challenges remain in the treatment of melanoma brain metastases. The development of more effective therapies requires continued investigation into the unique biology of brain metastases and novel approaches to overcome the blood-brain barrier.

References

1. AIM at Melanoma Foundation. Brain metastases [Internet]. AIM at Melanoma Foundation. [cited 2025 Oct 2]. Available from: https://www.aimatmelanoma.org/stages-of-melanoma/brain-metastases/
2. Metastatic melanoma [Internet]. StatPearls Publishing. [cited 2025 Oct 2]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470358/
3. Janavicius M, Lachej N, Anglickiene G, et al. Outcomes of treatment for melanoma brain metastases. J Skin Cancer 2020 Nov 5;2020:7520924
4. Eroglu Z, Topcu TO, Yu HM, et al. How I treat brain metastases of melanoma. ESMO Open. 2022 Volume 7, Issue 6, 100598
5. Zheng S, Lin Z, Zhang R, et al. Progress in immunotherapy for brain metastatic melanoma. Frontiers in Oncology. 2024;10.3389
6. Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. New England Journal of Medicine. 2018 Aug;379(8):722–30.
7. Tawbi HA, Forsyth PA, Hodi FS, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021 Dec;22(12):1692-1704.
8. Long GV, Atkinson V, Lo S, Guminski AD, et al. Five-year overall survival from the anti-PD1 brain collaboration (ABC Study). Journal of Clinical Oncology. 2021;39(15_suppl):9508.
9. Davies MA, Saiag P, Robert C, et al. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro-Oncology. 2021 Nov;23(11):1961–73.
10. Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. New England Journal of Medicine. 2019 Aug;381(7):626–36.
11. Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF V600–mutant melanoma brain metastases (COMBI-MB). Lancet Oncology. 2017;18(7):863–73.
12. Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma brain metastases (COLUMBUS brain study). Journal of Clinical Oncology. 2021;39(21):2391–401.
13. Queirolo P, Ascierto PA, Berrocal A, et al. Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study). Neuro-Oncology. 2025 Nov;26(11):2074–84.
14. Center for Drug Evaluation and Research. FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma [Internet]. U.S. Food and Drug Administration. [cited 2025 Oct 2]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma
15. Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. Journal of Clinical Oncology. 2021 Aug;39(24):2656–66.
16. Goff SL, Wang X, Madan RA, et al. Five-year follow-up of lifileucel in metastatic melanoma (C-144-01 study). Journal of Clinical Oncology. 2025;43(7_suppl):9507.
17. Betof Warner A, Smithy JW, Postow MA, et al. A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases. Journal of Clinical Oncology. 2024 Volume 42, Number 16_suppl TPS9603
18. Tehranian C, Fankhauser L, Harter PN, et al. The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis. Neuro-Oncology. 2022;24(2):213–27.
19. Ippen FM, Alvarez-Breckenridge CA, Kuter BM, et al. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. Neuro-Oncology. 2019 Nov;21(11):1401–11.
20. Zheng S, Lin Z, Zhang R, et al. Progress in immunotherapy for brain metastatic melanoma. Frontiers in Oncology. 2025;14:1485532.
21. Kluger HM, Chiang V, Maher EA, et al. Long-term survival of patients with melanoma with active brain metastases treated with immunotherapy. Cancer Immunology Research. 2021 Jan;9(1):116–25.
22. Demeule M, Régina A, Ché C, et al. Antibody drug conjugates with enhanced CNS penetration for brain metastases. Frontiers in Oncology. 2021;11:646303.
23. Moss NS, Tosi U, Santomasso BD, et al. Antibody drug conjugates in metastatic brain tumors. Journal of Neuro-Oncology. 2025;155:201–12.

Written by Sol Yohannes